Hansa Biopharma AB (publ) (STO:HNSA)
Sweden · Delayed Price · Currency is SEK 46.68
+3.90 (9.12%)
Sep 2, 2026, 5:29 PM CET
Hansa Biopharma AB Financials Overview
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 189.46 | 222.27 | 171.32 | 134.09 | 154.53 | 33.88 |
Revenue Growth | -3.57% | 29.74% | 27.76% | -13.22% | 356.12% | 455.56% |
Gross Profit Gross Profit Growth | 108.32 | 138.71 | 87.76 | 70.95 | 116.05 | 18.45 |
Operating Income Operating Income Growth | -577.53 | -522.58 | -632.22 | -791.16 | -576.12 | -539.58 |
Net Income Net Income Growth | -755.14 | -534.11 | -807.24 | -831.72 | -611.13 | -548.28 |
Earnings Per Share EPS Growth | -7.74 | -6.58 | -12.85 | -15.83 | -13.60 | -12.33 |
EPS Growth | - | - | - | - | - | - |
| Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Sweden Sweden Growth | - | 3.12 | - | 4.68 | - |
North America North America Growth | 14.09 | 27.96 | 27.42 | 64.27 | 15.71 |
Europe (Ex Sweden) Europe (Ex Sweden) Growth | 202.28 | 140.24 | 106.68 | 85.57 | 18.17 |
Rest of The World Rest of The World Growth | 5.9 | - | - | - | - |
Total Total Growth | 222.27 | 171.32 | 134.09 | 154.52 | 33.88 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 552.81 | 701.08 | 405.28 | 732.06 | 1,496 | 888.96 |
Total Debt Total Debt Growth | 1,034 | 938.67 | 1,079 | 866.77 | 791.09 | 35.38 |
Net Cash (Debt) Net Cash Growth | -480.99 | -237.59 | -673.73 | -134.71 | 705.09 | 853.58 |
Net Cash Growth | - | - | - | - | -17.40% | -37.81% |
Net Cash Per Share Net Cash Per Share Growth | -4.93 | -2.93 | -10.72 | -2.56 | 15.70 | 19.19 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -569.63 | -549.17 | -674.88 | -755.65 | -502.73 | -481.17 |
Capital Expenditures CapEx Growth | - | - | -0.12 | -0.28 | -3.33 | -2.4 |
Free Cash Flow Free Cash Flow Growth | -569.63 | -549.17 | -675 | -755.94 | -506.06 | -483.57 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 57.17% | 62.41% | 51.23% | 52.91% | 75.10% | 54.47% |
Operating Margin | -304.83% | -235.11% | -369.04% | -590.00% | -372.83% | -1592.71% |
Pretax Margin | -397.41% | -239.28% | -469.43% | -619.57% | -394.74% | -1617.95% |
Profit Margin | -398.58% | -240.30% | -471.20% | -620.25% | -395.49% | -1618.40% |
FCF Margin | -300.66% | -247.08% | -394.01% | -563.74% | -327.50% | -1427.38% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PS Ratio | 22.98 | 15.73 | 15.52 | 10.25 | 16.70 | 116.57 |